Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?

Annals of Surgical Oncology

Volumn 20, Issue 9, 2013, Pages 3009-3014

  Kurokawa, Yukinori ^a   Shibata, Taro ^b   Ando, Nobutoshi ^c   Seki, Shiko ^d   Mukaida, Hidenori ^e   Fukuda, Haruhiko ^b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c TOKYO DENTAL COLLEGE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^e HIROSHIMA CITY ASA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVOR; CLINICAL EVALUATION; CONTINUOUS INFUSION; DISEASE SEVERITY; ESOPHAGUS CANCER; FEMALE; HISTOLOGY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; THORACIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84881480531     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2946-1     Document Type: Article

References (20)

1. GLOBOCAN 2008. http://globocan.iarc.fr/.
2. Medical Research Council Oesophageal Cancer Working Group. GICAL resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-33.
3. Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.
4. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
6. Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 60-5.
7. Hirao M, Ando N, Tsujinaka T, et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 2011;98:1735-41.
8. Japanese Society for Esophageal Diseases. Guideline for clinical and pathological studies on carcinoma of the esophagus, ninth edition: part II. Esophagus. 2004;1:107-25.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
10. Brücher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300-9.
11. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-65.
12. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-8.
13. van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011;253:56-63.
14. Becker K, Fumagalli U, Mueller JD, et al. Preoperative chemotherapy for patients with locally advanced esophageal carcinoma: effect on tumor cell microinvolvement of regional lymph nodes. Cancer. 1999;85:1484-9.
15. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in esophageal carcinoma treated with preoperative chemotherapy. Cancer. 2003;98:1521-30.
16. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable esophageal carcinoma. J Clin Oncol. 2004;22:2774-80.
17. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized esophageal carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237-44.
18. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-7.
19. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-92.
20. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.